Oxygenta Pharmaceutical（524636）株式概要オキシジェンタ・ファーマシューティカル・リミテッドは、インドで医薬品原薬と医薬品有効成分を製造・販売している。 詳細524636 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 過去5年間で収益は年間38.3%減少しました。 キャッシュランウェイが1年未満である 意味のある時価総額がありません ( ₹2B )+1 さらなるリスクすべてのリスクチェックを見る524636 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,467 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA484,467 investors already sharing narrativesYour Fair Value₹Current Price₹49.0469.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-150m3b2016201920222025202620282031Revenue ₹3.5bEarnings ₹513.1mAdvancedSet Fair ValueView all narrativesOxygenta Pharmaceutical Limited 競合他社Syschem (India)Symbol: BSE:531173Market cap: ₹1.7bAccretion PharmaceuticalsSymbol: NSEI:ACCPLMarket cap: ₹1.9bBio Medica LaboratoriesSymbol: NSEI:BMLLMarket cap: ₹2.0bGennex LaboratoriesSymbol: BSE:531739Market cap: ₹2.2b価格と性能株価の高値、安値、推移の概要Oxygenta Pharmaceutical過去の株価現在の株価₹49.0452週高値₹103.5052週安値₹43.00ベータ0.751ヶ月の変化2.21%3ヶ月変化-9.72%1年変化-51.76%3年間の変化24.56%5年間の変化147.93%IPOからの変化2,235.24%最新ニュースお知らせ • Aug 01+ 2 more updatesOxygenta Pharmaceutical Limited to Report Q2, 2027 Results on Nov 14, 2026Oxygenta Pharmaceutical Limited announced that they will report Q2, 2027 results on Nov 14, 2026お知らせ • Jul 28Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026, at 10:30 Indian Standard Time.Reported Earnings • Jul 28First quarter 2027 earnings released: ₹0.57 loss per share (vs ₹1.65 loss in 1Q 2026)First quarter 2027 results: ₹0.57 loss per share (improved from ₹1.65 loss in 1Q 2026). Revenue: ₹370.2m (up 145% from 1Q 2026). Net loss: ₹21.0m (loss narrowed 66% from 1Q 2026). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.お知らせ • Jul 24Oxygenta Pharmaceutical Limited to Report Q1, 2027 Results on Jul 27, 2026Oxygenta Pharmaceutical Limited announced that they will report Q1, 2027 results at 12:15 PM, Indian Standard Time on Jul 27, 2026New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.最新情報をもっと見るRecent updatesお知らせ • Aug 01+ 2 more updatesOxygenta Pharmaceutical Limited to Report Q2, 2027 Results on Nov 14, 2026Oxygenta Pharmaceutical Limited announced that they will report Q2, 2027 results on Nov 14, 2026お知らせ • Jul 28Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026, at 10:30 Indian Standard Time.Reported Earnings • Jul 28First quarter 2027 earnings released: ₹0.57 loss per share (vs ₹1.65 loss in 1Q 2026)First quarter 2027 results: ₹0.57 loss per share (improved from ₹1.65 loss in 1Q 2026). Revenue: ₹370.2m (up 145% from 1Q 2026). Net loss: ₹21.0m (loss narrowed 66% from 1Q 2026). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.お知らせ • Jul 24Oxygenta Pharmaceutical Limited to Report Q1, 2027 Results on Jul 27, 2026Oxygenta Pharmaceutical Limited announced that they will report Q1, 2027 results at 12:15 PM, Indian Standard Time on Jul 27, 2026New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.お知らせ • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.お知らせ • Aug 26Oxygenta Pharmaceutical Limited Announces Change in Composition of Committees, Effective August 25, 2025Oxygenta Pharmaceutical Limited at its board meeting held on August 25, 2025 approved change in composition of committees of board effective August 25, 2025. Audit Committee,composed of Sidda Reddy Kanuparthi as Chairman, who is an Additional Director (Independent); Sharvari Swapnil Shinde as Member, also an Additional Director (Independent); Veera Reddy Arava as Member, an Additional Director (Independent); and Chandra Mouliswar Reddy as Member, who is an Additional Director (Executive). In the Nomination and Remuneration Committee, the composition includes Veera Reddy Arava as Chairman, an Additional Director (Independent); Sidda Reddy Kanuparthi as Member, an Additional Director (Independent); and Sharvari Swapnil Shinde as Member, who is an Additional Director (Independent).お知らせ • Aug 19+ 2 more updatesOxygenta Pharmaceutical Limited Announces Resignation of Vankineni Sai Sudhakar as Managing Director, Effective August 18, 2025Oxygenta Pharmaceutical Limited announced resignation of Vankineni Sai Sudhakar as Managing Director, effective August 18, 2025, due to change in ownership and management of the Company.Reported Earnings • Aug 16First quarter 2026 earnings released: ₹1.65 loss per share (vs ₹0.39 loss in 1Q 2025)First quarter 2026 results: ₹1.65 loss per share (further deteriorated from ₹0.39 loss in 1Q 2025). Revenue: ₹151.3m (up 20% from 1Q 2025). Net loss: ₹61.1m (loss widened 348% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 12Oxygenta Pharmaceutical Limited to Report Q1, 2026 Results on Aug 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q1, 2026 results on Aug 14, 2025New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹4.14b market cap, or US$48.2m).New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹4.60b market cap, or US$53.7m).Reported Earnings • Jun 02Full year 2025 earnings released: ₹2.86 loss per share (vs ₹1.09 loss in FY 2024)Full year 2025 results: ₹2.86 loss per share (further deteriorated from ₹1.09 loss in FY 2024). Revenue: ₹1.11b (up 179% from FY 2024). Net loss: ₹103.0m (loss widened 196% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 26Oxygenta Pharmaceutical Limited to Report Q4, 2025 Results on May 30, 2025Oxygenta Pharmaceutical Limited announced that they will report Q4, 2025 results on May 30, 2025Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹1.07 loss per share (vs ₹0.99 loss in 3Q 2024)Third quarter 2025 results: ₹1.07 loss per share (further deteriorated from ₹0.99 loss in 3Q 2024). Revenue: ₹336.9m (up 268% from 3Q 2024). Net loss: ₹39.3m (loss widened 17% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 08Oxygenta Pharmaceutical Limited to Report Q3, 2025 Results on Feb 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q3, 2025 results on Feb 14, 2025Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.81 (vs ₹0.87 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.81 (up from ₹0.87 loss in 2Q 2024). Revenue: ₹147.5m (up 13% from 2Q 2024). Net loss: ₹28.5m (loss narrowed 9.7% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.お知らせ • Nov 09Oxygenta Pharmaceutical Limited to Report Q2, 2025 Results on Nov 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Sep 12Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: survey no. 252/1,aroor village, sadasivapet mandal, sangareddy district, telangana - 502291, sangareddy IndiaReported Earnings • Aug 16First quarter 2025 earnings released: ₹0.39 loss per share (vs ₹1.65 loss in 1Q 2024)First quarter 2025 results: ₹0.39 loss per share (improved from ₹1.65 loss in 1Q 2024). Revenue: ₹126.4m (up 84% from 1Q 2024). Net loss: ₹13.6m (loss narrowed 70% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Aug 09Oxygenta Pharmaceutical Limited to Report Q1, 2025 Results on Aug 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q1, 2025 results on Aug 14, 2024お知らせ • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2024 Results on May 30, 2024Oxygenta Pharmaceutical Limited announced that they will report Q4, 2024 results on May 30, 2024New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹244m). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹1.30b market cap, or US$15.6m).お知らせ • May 23Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding from Amigos Molecular Solutions Private LimitedOn May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 1,700,000 shares to M V S Prasad Reddy, 200,000 shares to Amigos Molecular Solutions Private Limited and 100,000 to Rachamallu Aparna.お知らせ • Apr 09Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in fundingOxygenta Pharmaceutical Limited announced a private placement to issue 2,000,000 common shares at an issue price of INR 16 per share for the gross proceeds of INR 32,000,000 on April 8, 2024. The transaction will include participation from individual investors M VS Prasad Reddy for 200,000 shares, Rachamallu Aparna for 100,000 shares and Amigos Molecular Solutions Private Limited for 200,000 shares. The transaction has been approved by the shareholders of the company and is subject general shareholders which is to be scheduled on May 09, 2024.Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.87 loss per share (vs ₹1.64 loss in 2Q 2023)Second quarter 2024 results: ₹0.87 loss per share. Revenue: ₹130.8m (up 116% from 2Q 2023). Net loss: ₹31.6m (loss widened 35% from 2Q 2023).New Risk • Oct 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹113m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.02b market cap, or US$12.3m).お知らせ • Oct 12Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance OfficerOxygenta Pharmaceutical Limited at its board meeting held on October 11, 2023, based on the recommendation of Nomination and Remuneration Committee, approved the appointment of Miss. Dolly Mandhan as the Company Secretary of the Company (Membership No. A66040) designated as the Key Managerial Personnel pursuant to the provisions of section 203 of the Companies Act, 2013 and Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from 01st October 2023. Appointment to fill up vacancy due to resignation of Company Secretary. Miss. Dolly Mandhan is an Associate member of the Institute of Company Secretaries of India and a Commerce Graduate from North Maharashtra University. She has over 3 years of experience in dealing in secretarial functions and compliance matters.お知らせ • Sep 05+ 1 more updateOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023, at 15:00 Indian Standard Time. Location: at the registered office of the Company Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy District, Telangana IndiaNew Risk • Aug 18New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹151m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).Reported Earnings • Aug 18First quarter 2024 earnings released: ₹1.65 loss per share (vs ₹1.19 loss in 1Q 2023)First quarter 2024 results: ₹1.65 loss per share (further deteriorated from ₹1.19 loss in 1Q 2023). Revenue: ₹68.6m (down 23% from 1Q 2023). Net loss: ₹45.6m (loss widened 169% from 1Q 2023).お知らせ • Jul 03Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance OfficerOxygenta Pharmaceutical Limited announced that Mr. Veerendra Babu Rangisetti has resigned from the post of company secretary with effect from close of working hours of June 30, 2023. Consequent to his resignation as Company secretary, Mr. Veerendra Babu Rangisetti also ceases to be compliance officer of the Company.Reported Earnings • Jun 04Full year 2023 earnings released: ₹6.36 loss per share (vs ₹0.48 loss in FY 2022)Full year 2023 results: ₹6.36 loss per share (further deteriorated from ₹0.48 loss in FY 2022). Revenue: ₹310.1m (down 49% from FY 2022). Net loss: ₹115.7m (loss widened ₹109.6m from FY 2022).お知らせ • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2023 Results on May 30, 2023Oxygenta Pharmaceutical Limited announced that they will report Q4, 2023 results on May 30, 2023Reported Earnings • Feb 16Third quarter 2023 earnings released: ₹2.29 loss per share (vs ₹0.15 profit in 3Q 2022)Third quarter 2023 results: ₹2.29 loss per share (down from ₹0.15 profit in 3Q 2022). Revenue: ₹78.7m (down 51% from 3Q 2022). Net loss: ₹32.5m (down ₹34.7m from profit in 3Q 2022).Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.64 loss per share (vs ₹0.27 loss in 2Q 2022)Second quarter 2023 results: ₹1.64 loss per share (further deteriorated from ₹0.27 loss in 2Q 2022). Revenue: ₹60.6m (down 61% from 2Q 2022). Net loss: ₹23.4m (loss widened ₹19.5m from 2Q 2022).お知らせ • Nov 05Oxygenta Pharmaceutical Limited to Report Q2, 2023 Results on Nov 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q2, 2023 results on Nov 12, 2022お知らせ • Sep 06Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; to appoint a director in place of Sri. Raghavendra Rao Kanuganti, who retires by rotation and being eligible, seeks re-appointment; To consider Re-Appointment of Dr. Sai Sudhakar Vankineni as Managing Director of the Company; and to consider other matters.お知らせ • Aug 07Oxygenta Pharmaceutical Limited to Report Q1, 2023 Results on Aug 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q1, 2023 results on Aug 12, 2022Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹25.90, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.15 (down from ₹2.85 in 3Q 2021). Revenue: ₹159.3m (down 45% from 3Q 2021). Net income: ₹2.18m (down 93% from 3Q 2021). Profit margin: 1.4% (down from 10.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 09S.S. Organics Limited to Report Q3, 2022 Results on Feb 14, 2022S.S. Organics Limited announced that they will report Q3, 2022 results on Feb 14, 2022Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.35, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 237% over the past three years.Reported Earnings • Nov 21Second quarter 2022 earnings released: ₹0.27 loss per share (vs ₹0.67 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹154.9m (up 85% from 2Q 2021). Net loss: ₹3.88m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 13S.S. Organics Limited announced that it has received INR 40 million in fundingOn August 12, 2021, S.S. Organics Limited closed the transaction. The company issued 4,000,000 shares at issue price of INR 10 per share for gross proceeds of INR 40,000,000. The paid up share capital of the company will be increased to INR 140,213,000 post closing of the transaction.Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹12.19, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.株主還元524636IN PharmaceuticalsIN 市場7D-3.8%0.7%2.2%1Y-51.8%15.5%3.8%株主還元を見る業界別リターン: 524636過去 1 年間で15.5 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 524636は、過去 1 年間で3.8 % のリターンを上げたIndian市場を下回りました。価格変動Is 524636's price volatile compared to industry and market?524636 volatility524636 Average Weekly Movement8.0%Pharmaceuticals Industry Average Movement6.0%Market Average Movement6.0%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.7%安定した株価: 524636の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 524636の weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1990175n/awww.oxygentapharma.comオキシジェンタ・ファーマシューティカル・リミテッド（Oxygenta Pharmaceutical Limited）は、インドで医薬品原薬と医薬品有効成分を製造・販売している。医薬品製剤と有機ファインケミカルを提供。以前はS.S. Organics Limitedとして知られ、2022年2月にOxygenta Pharmaceutical Limitedに社名変更した。オキシジェンタ・ファーマシューティカル・リミテッドは1990年に設立され、インドのハイデラバードに拠点を置く。もっと見るOxygenta Pharmaceutical Limited 基礎のまとめOxygenta Pharmaceutical の収益と売上を時価総額と比較するとどうか。524636 基礎統計学時価総額₹1.81b収益（TTM）-₹135.69m売上高(TTM)₹1.35b1.3xP/Sレシオ-13.4xPER（株価収益率524636 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524636 損益計算書（TTM）収益₹1.35b売上原価₹1.17b売上総利益₹174.19mその他の費用₹309.88m収益-₹135.69m直近の収益報告Jun 30, 2026次回決算日Nov 14, 2026一株当たり利益（EPS）-3.67グロス・マージン12.92%純利益率-10.06%有利子負債／自己資本比率-256.7%524636 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 17:15終値2026/08/04 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oxygenta Pharmaceutical Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 01+ 2 more updatesOxygenta Pharmaceutical Limited to Report Q2, 2027 Results on Nov 14, 2026Oxygenta Pharmaceutical Limited announced that they will report Q2, 2027 results on Nov 14, 2026
お知らせ • Jul 28Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026, at 10:30 Indian Standard Time.
Reported Earnings • Jul 28First quarter 2027 earnings released: ₹0.57 loss per share (vs ₹1.65 loss in 1Q 2026)First quarter 2027 results: ₹0.57 loss per share (improved from ₹1.65 loss in 1Q 2026). Revenue: ₹370.2m (up 145% from 1Q 2026). Net loss: ₹21.0m (loss narrowed 66% from 1Q 2026). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.
お知らせ • Jul 24Oxygenta Pharmaceutical Limited to Report Q1, 2027 Results on Jul 27, 2026Oxygenta Pharmaceutical Limited announced that they will report Q1, 2027 results at 12:15 PM, Indian Standard Time on Jul 27, 2026
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).
Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.
お知らせ • Aug 01+ 2 more updatesOxygenta Pharmaceutical Limited to Report Q2, 2027 Results on Nov 14, 2026Oxygenta Pharmaceutical Limited announced that they will report Q2, 2027 results on Nov 14, 2026
お知らせ • Jul 28Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026Oxygenta Pharmaceutical Limited, Annual General Meeting, Aug 21, 2026, at 10:30 Indian Standard Time.
Reported Earnings • Jul 28First quarter 2027 earnings released: ₹0.57 loss per share (vs ₹1.65 loss in 1Q 2026)First quarter 2027 results: ₹0.57 loss per share (improved from ₹1.65 loss in 1Q 2026). Revenue: ₹370.2m (up 145% from 1Q 2026). Net loss: ₹21.0m (loss narrowed 66% from 1Q 2026). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.
お知らせ • Jul 24Oxygenta Pharmaceutical Limited to Report Q1, 2027 Results on Jul 27, 2026Oxygenta Pharmaceutical Limited announced that they will report Q1, 2027 results at 12:15 PM, Indian Standard Time on Jul 27, 2026
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m).
Reported Earnings • May 24Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025)Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m).
Reported Earnings • Feb 05Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025)Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year.
Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025)Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year.
お知らせ • Aug 29+ 3 more updatesOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 19, 2025, at 15:00 Indian Standard Time.
お知らせ • Aug 26Oxygenta Pharmaceutical Limited Announces Change in Composition of Committees, Effective August 25, 2025Oxygenta Pharmaceutical Limited at its board meeting held on August 25, 2025 approved change in composition of committees of board effective August 25, 2025. Audit Committee,composed of Sidda Reddy Kanuparthi as Chairman, who is an Additional Director (Independent); Sharvari Swapnil Shinde as Member, also an Additional Director (Independent); Veera Reddy Arava as Member, an Additional Director (Independent); and Chandra Mouliswar Reddy as Member, who is an Additional Director (Executive). In the Nomination and Remuneration Committee, the composition includes Veera Reddy Arava as Chairman, an Additional Director (Independent); Sidda Reddy Kanuparthi as Member, an Additional Director (Independent); and Sharvari Swapnil Shinde as Member, who is an Additional Director (Independent).
お知らせ • Aug 19+ 2 more updatesOxygenta Pharmaceutical Limited Announces Resignation of Vankineni Sai Sudhakar as Managing Director, Effective August 18, 2025Oxygenta Pharmaceutical Limited announced resignation of Vankineni Sai Sudhakar as Managing Director, effective August 18, 2025, due to change in ownership and management of the Company.
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹1.65 loss per share (vs ₹0.39 loss in 1Q 2025)First quarter 2026 results: ₹1.65 loss per share (further deteriorated from ₹0.39 loss in 1Q 2025). Revenue: ₹151.3m (up 20% from 1Q 2025). Net loss: ₹61.1m (loss widened 348% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 12Oxygenta Pharmaceutical Limited to Report Q1, 2026 Results on Aug 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q1, 2026 results on Aug 14, 2025
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹4.14b market cap, or US$48.2m).
New Risk • Jun 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹4.60b market cap, or US$53.7m).
Reported Earnings • Jun 02Full year 2025 earnings released: ₹2.86 loss per share (vs ₹1.09 loss in FY 2024)Full year 2025 results: ₹2.86 loss per share (further deteriorated from ₹1.09 loss in FY 2024). Revenue: ₹1.11b (up 179% from FY 2024). Net loss: ₹103.0m (loss widened 196% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 26Oxygenta Pharmaceutical Limited to Report Q4, 2025 Results on May 30, 2025Oxygenta Pharmaceutical Limited announced that they will report Q4, 2025 results on May 30, 2025
Reported Earnings • Feb 16Third quarter 2025 earnings released: ₹1.07 loss per share (vs ₹0.99 loss in 3Q 2024)Third quarter 2025 results: ₹1.07 loss per share (further deteriorated from ₹0.99 loss in 3Q 2024). Revenue: ₹336.9m (up 268% from 3Q 2024). Net loss: ₹39.3m (loss widened 17% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 08Oxygenta Pharmaceutical Limited to Report Q3, 2025 Results on Feb 14, 2025Oxygenta Pharmaceutical Limited announced that they will report Q3, 2025 results on Feb 14, 2025
Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.81 (vs ₹0.87 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.81 (up from ₹0.87 loss in 2Q 2024). Revenue: ₹147.5m (up 13% from 2Q 2024). Net loss: ₹28.5m (loss narrowed 9.7% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
お知らせ • Nov 09Oxygenta Pharmaceutical Limited to Report Q2, 2025 Results on Nov 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Sep 12Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: survey no. 252/1,aroor village, sadasivapet mandal, sangareddy district, telangana - 502291, sangareddy India
Reported Earnings • Aug 16First quarter 2025 earnings released: ₹0.39 loss per share (vs ₹1.65 loss in 1Q 2024)First quarter 2025 results: ₹0.39 loss per share (improved from ₹1.65 loss in 1Q 2024). Revenue: ₹126.4m (up 84% from 1Q 2024). Net loss: ₹13.6m (loss narrowed 70% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Aug 09Oxygenta Pharmaceutical Limited to Report Q1, 2025 Results on Aug 14, 2024Oxygenta Pharmaceutical Limited announced that they will report Q1, 2025 results on Aug 14, 2024
お知らせ • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2024 Results on May 30, 2024Oxygenta Pharmaceutical Limited announced that they will report Q4, 2024 results on May 30, 2024
New Risk • May 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹244m). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹1.30b market cap, or US$15.6m).
お知らせ • May 23Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding from Amigos Molecular Solutions Private LimitedOn May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 1,700,000 shares to M V S Prasad Reddy, 200,000 shares to Amigos Molecular Solutions Private Limited and 100,000 to Rachamallu Aparna.
お知らせ • Apr 09Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in fundingOxygenta Pharmaceutical Limited announced a private placement to issue 2,000,000 common shares at an issue price of INR 16 per share for the gross proceeds of INR 32,000,000 on April 8, 2024. The transaction will include participation from individual investors M VS Prasad Reddy for 200,000 shares, Rachamallu Aparna for 100,000 shares and Amigos Molecular Solutions Private Limited for 200,000 shares. The transaction has been approved by the shareholders of the company and is subject general shareholders which is to be scheduled on May 09, 2024.
Reported Earnings • Nov 18Second quarter 2024 earnings released: ₹0.87 loss per share (vs ₹1.64 loss in 2Q 2023)Second quarter 2024 results: ₹0.87 loss per share. Revenue: ₹130.8m (up 116% from 2Q 2023). Net loss: ₹31.6m (loss widened 35% from 2Q 2023).
New Risk • Oct 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹113m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.02b market cap, or US$12.3m).
お知らせ • Oct 12Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance OfficerOxygenta Pharmaceutical Limited at its board meeting held on October 11, 2023, based on the recommendation of Nomination and Remuneration Committee, approved the appointment of Miss. Dolly Mandhan as the Company Secretary of the Company (Membership No. A66040) designated as the Key Managerial Personnel pursuant to the provisions of section 203 of the Companies Act, 2013 and Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from 01st October 2023. Appointment to fill up vacancy due to resignation of Company Secretary. Miss. Dolly Mandhan is an Associate member of the Institute of Company Secretaries of India and a Commerce Graduate from North Maharashtra University. She has over 3 years of experience in dealing in secretarial functions and compliance matters.
お知らせ • Sep 05+ 1 more updateOxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2023, at 15:00 Indian Standard Time. Location: at the registered office of the Company Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy District, Telangana India
New Risk • Aug 18New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹151m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).
Reported Earnings • Aug 18First quarter 2024 earnings released: ₹1.65 loss per share (vs ₹1.19 loss in 1Q 2023)First quarter 2024 results: ₹1.65 loss per share (further deteriorated from ₹1.19 loss in 1Q 2023). Revenue: ₹68.6m (down 23% from 1Q 2023). Net loss: ₹45.6m (loss widened 169% from 1Q 2023).
お知らせ • Jul 03Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance OfficerOxygenta Pharmaceutical Limited announced that Mr. Veerendra Babu Rangisetti has resigned from the post of company secretary with effect from close of working hours of June 30, 2023. Consequent to his resignation as Company secretary, Mr. Veerendra Babu Rangisetti also ceases to be compliance officer of the Company.
Reported Earnings • Jun 04Full year 2023 earnings released: ₹6.36 loss per share (vs ₹0.48 loss in FY 2022)Full year 2023 results: ₹6.36 loss per share (further deteriorated from ₹0.48 loss in FY 2022). Revenue: ₹310.1m (down 49% from FY 2022). Net loss: ₹115.7m (loss widened ₹109.6m from FY 2022).
お知らせ • May 25Oxygenta Pharmaceutical Limited to Report Q4, 2023 Results on May 30, 2023Oxygenta Pharmaceutical Limited announced that they will report Q4, 2023 results on May 30, 2023
Reported Earnings • Feb 16Third quarter 2023 earnings released: ₹2.29 loss per share (vs ₹0.15 profit in 3Q 2022)Third quarter 2023 results: ₹2.29 loss per share (down from ₹0.15 profit in 3Q 2022). Revenue: ₹78.7m (down 51% from 3Q 2022). Net loss: ₹32.5m (down ₹34.7m from profit in 3Q 2022).
Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.64 loss per share (vs ₹0.27 loss in 2Q 2022)Second quarter 2023 results: ₹1.64 loss per share (further deteriorated from ₹0.27 loss in 2Q 2022). Revenue: ₹60.6m (down 61% from 2Q 2022). Net loss: ₹23.4m (loss widened ₹19.5m from 2Q 2022).
お知らせ • Nov 05Oxygenta Pharmaceutical Limited to Report Q2, 2023 Results on Nov 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q2, 2023 results on Nov 12, 2022
お知らせ • Sep 06Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; to appoint a director in place of Sri. Raghavendra Rao Kanuganti, who retires by rotation and being eligible, seeks re-appointment; To consider Re-Appointment of Dr. Sai Sudhakar Vankineni as Managing Director of the Company; and to consider other matters.
お知らせ • Aug 07Oxygenta Pharmaceutical Limited to Report Q1, 2023 Results on Aug 12, 2022Oxygenta Pharmaceutical Limited announced that they will report Q1, 2023 results on Aug 12, 2022
Valuation Update With 7 Day Price Move • May 18Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹25.90, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years.
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.15 (down from ₹2.85 in 3Q 2021). Revenue: ₹159.3m (down 45% from 3Q 2021). Net income: ₹2.18m (down 93% from 3Q 2021). Profit margin: 1.4% (down from 10.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 09S.S. Organics Limited to Report Q3, 2022 Results on Feb 14, 2022S.S. Organics Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.35, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 237% over the past three years.
Reported Earnings • Nov 21Second quarter 2022 earnings released: ₹0.27 loss per share (vs ₹0.67 loss in 2Q 2021)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹154.9m (up 85% from 2Q 2021). Net loss: ₹3.88m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 13S.S. Organics Limited announced that it has received INR 40 million in fundingOn August 12, 2021, S.S. Organics Limited closed the transaction. The company issued 4,000,000 shares at issue price of INR 10 per share for gross proceeds of INR 40,000,000. The paid up share capital of the company will be increased to INR 140,213,000 post closing of the transaction.
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹12.19, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years.
